Opinion & analysis

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

Estée Lauder’s CEO revealed that “a small group of employees” was responsible for intentionally altering test results behind product claims. The shocking disclosure was mitigated by the fact that the problem was discovered internally. Nevertheless, stock tumbled following the announcement–but has largely recovered. Find out how the disclosure may affect Lauder moving forward, and learn how analysts reacted

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

Takeda/Shire Merger: Five Things To Worry About

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

Pfizer’s Reference Point on Trial Innovation : Ask the Patient

US FDA Commissioner: Agency Will Propose New Rule That Blends Quality System Regulation, ISO 13485

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?

GSK’s Head Of Artificial Intelligence Unveils R&D Goals

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View